Filter documents Clear search

pdf icon

FSRH CEU Statement: Contraception for Women with Eating Disorders - May 2018

File size: 213kb | Date: 29 May 2018 | Clinical Statements - PDF

Sexually active women of reproductive age with eating disorders require effective contraception despite the fact that amenorrhoea and anovulation are common in this population. This statement provides clinicians with a resource for best helping women with eating disorders choose the most appropriate and acceptable contraception for them. Download and save the document here.

pdf icon

FSRH CEU Statement to published systematic review: The relationship between progestin hormonal contraception and depression: a systematic review

File size: 127kb | Date: 9 March 2018 | Clinical Statements - PDF

Much recent media attention has been given to the subject of a potential association between hormonal contraception and depression. The FSRH CEU monitors and reports relevant emerging evidence. A new systematic review published in Contraception examines the existing evidence relating to risk of depression associated with use of progestogen-only contraception (POC).1 The authors of the review conclude that the bulk of the evidence does not support an association between use of POC and depression based on validated measures. Meta-analysis was not possible due to the heterogeneity of studies.

pdf icon

FSRH CEU response to European Medicines Agency recommendations regarding use of ulipristal acetate for management of uterine fibroids

File size: 225kb | Date: 12 February 2018 | Clinical Statements - PDF

The European Medicines Agency (EMA) is currently reviewing the safety of use of Esmya® (ulipristal acetate) for management of uterine fibroids. This review follows reports of a very small number of cases worldwide of serious liver injury in women using Esmya. Until the review process is complete, temporary restrictions have been placed on commencing treatment with Esmya and guidelines for monitoring liver function in women already taking Esmya have been introduced. The EMA recommendations are available at:

pdf icon

FSRH CEU Statement: Response to Study Intrauterine Contraception Use and Cervical Cancer Risk - January 2018

File size: 139kb | Date: 18 January 2018 | Clinical Statements - PDF

This statement responds to a recent study that reported that women who had used intrauterine contraception (IUC) were over one third less likely to experience invasive cervical cancer than women who had not used IUC. The study has received media attention and the FSRH CEU considered it important to put the findings into perspective. January 2018

pdf icon

FSRH CEU Statement: Response to Study Contemporary Hormonal Contraception and the Risk of Breast Cancer

File size: 472kb | Date: 11 December 2017 | Clinical Statements - PDF

FSRH's Clinical Effectiveness Unit (CEU) reviews an observational study published in the New England Journal of Medicine. The study reports that, in the Danish study population, women who were currently using any method of hormonal contraception* (HC) or had done so within the last 6 months were 20% more likely to be diagnosed with breast cancer than those who had never used HC.

pdf icon

CEU Statement: Weight and contraception (April 2017)

File size: 212kb | Date: 24 April 2017 | Clinical Statements - PDF

This statement summarises the available evidence regarding how contraception may affect a woman’s weight and how a woman’s weight may affect contraceptive efficacy. Looking at each method individually, the CEU advises clinicians on what proven and theoretical associations exist between contraception and weight.

pdf icon

FSRH CEU Statement: Management of women taking anticoagulants or antiplatelet medications who request intrauterine contraception or subdermal implants - March 2017

File size: 292kb | Date: 29 March 2017 | Clinical Statements - PDF

This statement aims to encourage the consistent and safe management of women requesting intrauterine contraception (IUC) and subdermal implants (SDI) who are taking anticoagulants or antiplatelet medications. It is primarily aimed at clinicians working in primary care and community sexual and reproductive health clinics.